Search by conditions:


Protocol Description Phase
15-096 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy  (View details on Phase II
13-523 A Phase 1 Study of LY3009120 in Patients with Advanced or Metastatic Cancer  (View details on Phase I
14-271 A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alterations  (View details on Phase I
14-332 A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma  (View details on Phase II
12-487 A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors  (View details on Phase I
13-240 A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma  (View details on Phase I
14-121 A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)  (View details on Phase II
12-376 A Phase Ib, Open-Label Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma  (View details on Phase I
14-062 A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain  (View details on Phase II
16-703 A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma  (View details on Phase III
13-465 ECOG 3612: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma  (View details on Phase II
14-186 Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients With BRAF-Mutant Melanoma and Other Solid Tumors  (View details on Phase I
13-424 Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors  (View details on Phase II
15-724 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma  (View details on Phase III
14 clinical trials listed

Back to Top